Financials VALBIOTIS

Equities

Market Closed - Euronext Paris Other stock markets 11:35:26 2024-04-26 am EDT			5-day change	1st Jan Change
3.9 ^EUR	-1.64%		+0.91%	-22.00%

Apr. 26	Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 03	Valbiotis: launch of Valbiotis PRO Cholesterol in May	CF

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024	2025
Capitalization ¹	13.48	16.09	46.58	66.56	44.66	61.51	61.51	-
Enterprise Value (EV) ¹	6.061	8.057	39.01	52.33	31.01	41.76	43.26	22.06
P/E ratio	-	-1.9 x	-11.7 x	-7.29 x	-2.98 x	-4.17 x	-4.53 x	45.9 x
Yield	-	-	-	-	-	-	-	-
Capitalization / Revenue	8.93 x	8.41 x	9.13 x	24.7 x	15.9 x	9.27 x	7.32 x	2.55 x
EV / Revenue	4.02 x	4.21 x	7.65 x	19.4 x	11 x	6.3 x	5.15 x	0.91 x
EV / EBITDA	-	-	-16.5 x	-6.95 x	-2.77 x	-4.86 x	-3.64 x	-2.48 x
EV / FCF	-1.15 x	-1.54 x	16.5 x	-7.01 x	-3.33 x	-4.05 x	-5.98 x	4.24 x
FCF Yield	-86.9%	-65%	6.05%	-14.3%	-30%	-24.7%	-16.7%	23.6%
Price to Book	-	-	6.53 x	4.66 x	3.34 x	3.12 x	2.85 x	1.3 x
Nbr of stocks (in thousands)	4,135	7,183	7,686	9,717	12,405	15,773	15,773	-
Reference price ²	3.260	2.240	6.060	6.850	3.600	3.900	3.900	3.900
Announcement Date	3/8/19	4/21/20	3/16/21	3/15/22	3/15/23	-	-	-

¹EUR in Million²EUR

Estimates

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024	2025
Net sales ¹	1.509	1.913	5.099	2.693	2.814	6.633	8.4	24.13
EBITDA ¹	-	-	-2.37	-7.534	-11.17	-8.6	-11.9	-8.9
EBIT ¹	-4.876	-5.157	-3.407	-8.475	-12.03	-10.4	-12.8	3.55
Operating Margin	-323.13%	-269.58%	-66.82%	-314.7%	-427.36%	-156.78%	-152.38%	14.71%
Earnings before Tax (EBT)	-	-	-3.829	-	-	-	-	-
Net income ¹	-4.967	-5.504	-3.829	-8.681	-12.31	-10.55	-13	2.3
Net margin	-329.16%	-287.72%	-75.09%	-322.35%	-437.53%	-159.05%	-154.76%	9.53%
EPS ²	-	-1.180	-0.5200	-0.9400	-1.210	-0.9350	-0.8600	0.0850
Free Cash Flow ¹	-5.269	-5.236	2.361	-7.462	-9.303	-10.3	-7.233	5.2
FCF margin	-349.17%	-273.71%	46.3%	-277.09%	-330.6%	-155.28%	-86.11%	21.55%
FCF Conversion (EBITDA)	-	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-	226.09%
Dividend per Share	-	-	-	-	-	-	-	-
Announcement Date	3/8/19	4/21/20	3/16/21	3/15/22	3/15/23	-	-	-

¹EUR in Million²EUR

Estimates

Fiscal Period: December	2018	2019	2020	2021	2022	2023	2024	2025
Net Debt ¹	-	-	-	-	-	-	-	-
Net Cash position ¹	7.42	8.03	7.57	14.2	13.7	19.8	18.3	39.5
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow ¹	-5.27	-5.24	2.36	-7.46	-9.3	-10.3	-7.23	5.2
ROE (net income / shareholders' equity)	-	-	-49.7%	-81%	-	-57.7%	-60.5%	-22.3%
ROA (Net income/ Total Assets)	-	-	-	-	-	-	-	15.3%
Assets ¹	-	-	-	-	-	-	-	15.03
Book Value Per Share ²	-	-	0.9300	1.470	1.080	1.250	1.370	3.000
Cash Flow per Share ²	-	-1.050	0.3600	-0.7800	-0.9100	-0.8000	-0.1000	1.200
Capex ¹	0.72	0.29	0.33	0.31	0.11	0.3	0.35	0.35
Capex / Sales	47.91%	15.16%	6.51%	11.36%	3.94%	4.52%	4.17%	1.45%
Announcement Date	3/8/19	4/21/20	3/16/21	3/15/22	3/15/23	-	-	-

¹EUR in Million²EUR

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.9 EUR

Average target price

10.07 EUR

Spread / Average Target

+158.12%

	1st Jan change	Capi.
VALBIOTIS	-22.00%	65.67M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B